Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apitox add-on therapy in MS
NCT03710655Phase 3Unknown
- Sponsor
- Apimeds Pharmaceuticals US, Inc.
- Start
- Apr 2019
- Primary completion
- Aug 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of apis mellifera venom in multiple sclerosis (MS), sponsored by Apimeds Pharmaceuticals US, Inc. Primary endpoints: Expanded Disability Status Scale at 16 weeks, Multiple Sclerosis Functional Composite at 16 weeks and 1 more. Status: unknown.
02
Drugs
apis mellifera venom
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03710655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03710655.